|
|
|
|
| LEADER |
01911 am a22002173u 4500 |
| 001 |
74036 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Carter, Scott L.
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Carter, Scott L.
|e contributor
|
| 100 |
1 |
0 |
|a Lander, Eric S.
|e contributor
|
| 700 |
1 |
0 |
|a Lander, Eric S.
|e author
|
| 245 |
0 |
0 |
|a The genomic complexity of primary human prostate cancer
|
| 260 |
|
|
|b Nature Publishing Group,
|c 2012-10-17T16:07:54Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/74036
|
| 520 |
|
|
|a 2011 August 10.
|
| 520 |
|
|
|a Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. Several tumours contained complex chains of balanced (that is, 'copy-neutral') rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2-ERG, but inversely correlated with these regions in tumours lacking ETS fusions. This observation suggests a link between chromatin or transcriptional regulation and the genesis of genomic aberrations. Three tumours contained rearrangements that disrupted CADM2, and four harboured events disrupting either PTEN (unbalanced events), a prostate tumour suppressor, or MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms.
|
| 520 |
|
|
|a National Human Genome Research Institute (U.S.)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Nature
|
